Neuropeutics Inc announces a collaboration with LifeArc to develop a new small molecule for the treatment of motor neuron disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS).

Coya Therapeutics is entering into a phase 2b study for its ALS, and the biotech’s CEO believes it’s on the cusp of a game changer.

A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...

The ALS Association will host its second ALS Nexus conference in August, with the goal of making the disease a livable one ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Alchemab Therapeutics has entered a collaboration with Lilly to discover novel therapeutic candidates to treat amyotrophic ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

At the beginning of 2025 I knocked on the door of Cai Lei former executive of a major listed company in Beijing When I entered the room he was par ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

Zydus Lifesciences's Usnoflast receives Orphan Drug Designation from the USFDA for the treatment of Amyotrophic Lateral ...